Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer.

Treatment of advanced PCa should be personalized, with administration of a combination of androgen deprivation therapy, ARAT agents, and chemotherapy being based on the patient's safety profile and the risk of side effects.